PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

Functional claims for pharmaceutical formulations: Validity versus enforcement (T 2130/22)

  • Technology: Pharmaceuticals
  • 24th January 2025
Stack of gold slabs with a glowing turquoise middle layer on dark blue, Evolve abstract article image.

This post is based on a previous article on IPKat.

The Board of Appeal decision in T 2130/22 considered the inventive step of a pharmaceutical formulation in which the technical effect relied upon for inventive step was also a functional feature of the claim. The decision confirms that when a technical effect is specified as a functional feature in a claim, arguments regarding lack of demonstration of the effect across the whole scope of the claim will be considered by the EPO under the heading of sufficiency rather than that of inventive step. The claims in this case also highlight the need for patentees to be mindful of the potential enforceability of functional claim language. 

Legal background: Functional features, sufficiency and inventive step

The assessment of inventive step at the EPO requires identification of the technical effect of the claimed invention over the closest prior art. When the technical effect is not specified in the claim, but rather relied upon for inventive step, there may be an issue if the effect is not demonstrated across the scope of the claim. However, when the technical effect is specified as a functional feature in the claim itself, the situation is different. As explained by the Enlarged Board of Appeal (EBA) in G 1/03, when an effect is part of the claim, objections regarding whether the effect is achieved across the scope of the claim should be considered under sufficiency of disclosure rather than inventive step (see G 1/03 point 2.5.2).

In contrast to the EPO, UK courts have shown a tendency to consider the technical effect of an invention as a claimed feature regardless of whether it is explicitly included in the claim. This means that in the UK, evidence for both claimed and unclaimed technical effects relied on for inventive step may be considered under a unified “plausibility” analysis. This was highlighted in UK decisions such as Astellas v Teva [2023] EWHC 2571 (Pat) in which the court construed a claim as inherently requiring the technical effect relied on for inventive step, even though this effect was not explicitly claimed. 

Case Background: Stabilising submicron particles for ophthalmic delivery

The patent at issue in the case (EP 3470059, Bausch & Lomb) related to an ophthalmic suspension formulation of loteprednol etabonate (LE) (marketed as Lotemax). The formulation was indicated to be storage stable for at least one year whilst retaining submicron particles of the active ingredient. The Opposition Division maintained the patent in amended form, and the Opponent (Sandoz) appealed.

Claim 1 on appeal specified “an ophthalmic suspension comprising an ophthalmic active ingredient suspended in a formulation vehicle, wherein the […] formulation vehicle comprises […] hydroxypropylmethyl cellulose […] and wherein the suspension is storage stable for at least one year.” The key issues on appeal were sufficiency of disclosure and inventive step. The Opponent argued that the skilled person would not be able to prepare stable formulations across the scope of the claim using any grade and amount of hydroxypropylmethyl cellulose (HPMC). The Opponent also argued that the claimed formulation lacked inventive step over several prior art documents disclosing LE formulations.

Sufficiency of disclosure of functional features

The Board of Appeal found that the patent provided clear guidance on how to achieve the claimed functional feature of “storage stable for at least one year”. Particularly, the Board of Appeal found that the application as filed provided sufficient detailed information on how this could be achieved, given that the description gave specific concentration ranges for the critical components. The Board of Appeal noted that “the Table in paragraph [0043] gives the specific amounts of polycarbophil and HPMC, i.e. 0.1-0.5% by weight for both components, which are necessary to perform the claimed invention when LE is used as active agent” (r.2.2).

The Opponent argued that the skilled person would not be able to prepare stable formulations across the scope of the claim using any grade and amount of HPMC. However, the Board of Appeal found this argument unconvincing given the clear guidance in the description on suitable grades and concentrations of HPMC, as well as experimental data showing which formulations achieved the required stability.

The Board of Appeal thus found the functional feature of the formulation to be sufficiently disclosed given that the application as filed went beyond merely asserting the function was achieved, but instead provided specific working ranges for critical components, a technical explanation of the stabilisation mechanism, experimental data showing which formulations worked and which did not, and long-term stability data confirming the claimed effect.

Inventive step of functional features

The document considered by the Board of Appeal as the closest prior art for inventive step analysis disclosed a gel formulation of LE that was storage stable but did not have submicron particle size or contain HPMC. The technical problem was defined as the provision of an LE formulation having improved efficacy while maintaining storage stability. 

The Board of Appeal found that none of the cited prior art documents provided a motivation to add HPMC to improve both the stability and efficacy of submicron LE particles in a polycarbophil formulation. The Board of Appeal particularly noted that “HPMC forms a more compact structure that can enhance the viscosity within the polycarbophil matrix, thereby reducing the particle movement and also inhibiting nucleation, thereby stabilising the small particles by reducing the Ostwald ripening effect” (r. 4.3.2).

The Board of Appeal thus set aside the Opposition Division’s decision and ordered that the patent be maintained according to the main request (filed as auxiliary request 1), which was identical to claim 1 as granted with some amendments to dependent claims. The case was remitted to the Opposition Division with the order to maintain the patent based on the main request, subject to any necessary adaptation of the description.

Final thoughts

In this case, the Board of Appeal rejected the Opponent’s argument that the technical effect had not been shown across the scope of the claim. Citing G 1/03, the Board of Appeal explained that since the storage stability was a functional feature of the claim, this objection was more appropriately considered under sufficiency rather than inventive step (r. 4.3.3). However, it is not clear that assessment of the functional effect under inventive step would have led to a different outcome for the case overall. Regardless of whether the effect was considered as a feature of the claim, according to the principles established in the case law, the same test for the standard of evidence would apply (i.e. would a skilled person have substantiated doubts about the claimed/unclaimed effect). The issue of whether the feature in question should be considered under the heading of sufficiency or inventive step therefore appears to be a red herring in this instance. In fact, consideration of the feature solely under inventive step may have helped the Patentee by reducing the disclosure requirement for the technical effect in the application as filed (per G 2/21).  It must also be noted that, despite the obvious advantages of functional claiming in terms of breadth of scope, care must still be taken with functional features. If a patent is to be successfully enforced, the claimed functional features of a product must also be easy to test for the purposes of successful enforcement against potential infringers. In order to enforce their patent, the patentee in this case would need to provide convincing evidence that the alleged infringing formulations have the claimed feature of being “storage stable for at least one year”. This might be a rather time-consuming feature to test! 

Related insights...

Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.

Not just synergy: Other ways to support a drug combo invention (T 0593/24)

  • 17th November 2026
It is often necessary to support a drug combination invention with synergy data. This can be a problem for innovators, given that synergy data may not be assessed in the clinic, as additive effects may be sufficient for regulatory approval. However, T 0593/24 is a reminder that, if you lack synergy data, this may not…
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image

Fractional IP counsel for biotech: what to look for in a fractional IP adviser

  • 16th November 2026
What to look for in part-time senior IP support for a growing biotech, from Series A to partnering and acquisition, and how experienced fractional IP counsel can help at every stage.
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

Post-published clinical data does not always save you (T 0251/25, Empagliflozin)

  • 3rd November 2026
Empagliflozin (Jardiance) is approved in the US for reducing the risk of cardiovascular death in adults with type 2 diabetes (T2D) and established cardiovascular disease, and in Europe for reducing the risk of cardiovascular death and hospitalisation for heart failure in adults with heart failure. The recent decision in T 0251/25 nonetheless found Boehringer Ingelheim’s…
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image

Reformatio in peius survives a procedural violation (T 1168/24)

  • 2nd November 2026
Sometimes patent law is about procedures and not inventions. The appeal in T 1168/24 related to the lipid nanoparticle (LNP) technology behind the COVID-19 vaccines, opposed by Merck and Moderna. After two rounds of opposition and two appeals, the patent was revoked for added matter. Whilst the global litigation surrounding LNPs is interesting in its…
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

The enablement paradox and the danger of definitions (Wyeth v AstraZeneca)

  • 6th October 2026
The Federal Circuit’s decision in Wyeth v AstraZeneca (No. 2024-2325) applied the enablement test to a dose invention. The case is an interesting contrast to the other recent case to apply enablement to a method of treatment claim, Teva v Eli Lilly.
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image

Lack of clarity by the backdoor: An ambiguity “may simply result in a broader interpretation” (T 0977/25)

  • 4th October 2026
In T 0977/25, a Board of Appeal found that the word “it” in an amended method claim for an e-cigarette cartridge was ambiguous.
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image

G1/25: What are the consequences?

  • 12th September 2026
Following the release of G1/25, questions have been circling as to what the decision means for the pending referral in G 1/26 and what the consequences (good or bad) are for applicants and patentees.
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

BREAKING: When real doubt hits – G1/25 changes the description adaptation requirement for the worse

  • 4th September 2026
G 1/25, issued today, holds that the description must be adapted only where an “inconsistency” between the claims and description causes non-compliance with another requirement of the EPC.
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image

New referral on claim interpretation and relevance of G1/24 to added matter confirmed (G1/26)

  • 23rd July 2026
We now have confirmation of a new referral to the EBA on claim interpretation (G1/26). As previously hinted, the Board of Appeal in T 0873/24 has decided to refer questions on the application of G1/24 to the assessment of added matter.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.

When do you file for a drug combination invention? (T 592/24)

  • 16th July 2026
Drug combination inventions are increasingly difficult to protect. File too early for a drug-combination invention and the application may lack the data to support the non-obvious effect of the combination. Wait for the trial read-out, and a competitor, or your own published protocol, may have already placed the invention in the public domain. 
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice